OQS
DAWN

Occudo Quantitative Strategies’s Day One Biopharmaceuticals DAWN Stock Holding History

Occudo Quantitative Strategies’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,947
Closed -$280K – 1067
2023
Q1 		$280K Buy
+20,947
New +$409K 0.03% 669
2022
Q3 		– Sell
-23,619
Closed -$423K – 1233
2022
Q2 		$423K Buy
+23,619
New +$244K 0.03% 676

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

Occudo Quantitative Strategies's DAWN Position: Q2 2023 in Review

Occudo Quantitative Strategies sold out of Day One Biopharmaceuticals (DAWN) in Q2 2023, closing a stake of 20,947 shares — an estimated $280K sold.

Occudo Quantitative Strategies first reported a position in DAWN in Q2 2022 and held it in 2 quarters. The position peaked at $423K in Q2 2022. 140 funds tracked by Wall St. Rank hold DAWN as of Q2 2023.

  • Occudo Quantitative Strategies reported no remaining Day One Biopharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 20,947 Day One Biopharmaceuticals shares in Q2 2023, an estimated $280K.
  • Occudo Quantitative Strategies first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Occudo Quantitative Strategies's Day One Biopharmaceuticals position peaked at $423K in Q2 2022.
  • 140 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.